ReviewCurrent problems in cancer
United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies.
Review in Current problems in cancer. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study.Cancer chemotherapy and pharmacology · 2024Trial
- Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors.Cancer chemotherapy and pharmacology · 2014Trial
- Design, synthesis, and biological evaluation of KA7, a novel quinolone-based sorafenib analogue with potent anticancer and immunomodulatory activities.RSC advances · 2025Article
- Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study.NPJ precision oncology · 2025Article
- Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice.Heliyon · 2024Review
- Progression of oncolytic virus in liver cancer treatment.Frontiers in oncology · 2024Review
- Review
- Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition.Cancer research · 2023Article
- Article
- Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected Mice.bioRxiv : the preprint server for biology · 2021Article
- Pharmacophore-based virtual screening, synthesis, biological evaluation, and molecular docking study of novel pyrrolizines bearing urea/thiourea moieties with potential cytotoxicity and CDK inhibitory activities.Journal of enzyme inhibition and medicinal chemistry · 2021Article
- Article
- Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma.Scientific reports · 2021Article
- Extracellular Vesicles Act as Nano-Transporters of Tyrosine Kinase Inhibitors to Revert Iodine Avidity in Thyroid Cancer.Pharmaceutics · 2021Article
- Targeting Molecular Inflammatory Pathways in Granuloma as Host-Directed Therapies for Tuberculosis.Frontiers in immunology · 2021Review
- Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors.Pharmaceutics · 2020Review
- Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy.Frontiers in chemistry · 2020Review
- The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea.Breast cancer research and treatment · 2019Review
- Article
- Indoleamine 2, 3-Dioxygenase-Mediated Tryptophan Catabolism: A Leading Star or Supporting Act in the Tuberculosis and HIV Pas-de-Deux?Frontiers in cellular and infection microbiology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.